NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
Clinical Trials
83 trialsNCT06077500 2026-01-06
DAREONᵀᴹ-8
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT03043872 2025-10-21
CASPIAN
AstraZeneca
Phase 3 Active not recruiting
NCT05599984 2025-10-20
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT06838208 2025-09-24
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT05796089 2025-08-26
CHEST RT
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03382561 2025-07-03
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04774380 2025-05-23
LUMINANCE
AstraZeneca
Phase 3 Completed
NCT06951841 2025-04-30
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
Phase 4 Not yet recruiting
NCT06931145 2025-04-23
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT04005716 2025-02-28
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT06480864 2025-01-06
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
China Medical University, China
Phase NA Recruiting
NCT06732258 2024-12-27
Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Phase 1 Not yet recruiting
NCT04951115 2024-11-26
A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer
Weill Medical College of Cornell University
Phase 2 Terminated
NCT05566041 2024-10-31
REPLATINUM
EpicentRx, Inc.
Phase 3 Active not recruiting
NCT02815592 2024-09-04
Trial of BMS-986012 in Combination With Platinum and Etoposide
Bristol-Myers Squibb
Phase 1 Completed
NCT03850067 2024-08-26
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
Celgene
Phase 1 Completed
NCT00791154 2024-08-23
SCLC
NantCell, Inc.
Phase 1/2 Terminated
NCT06536868 2024-08-05
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC
Second Hospital of Shanxi Medical University
Phase 2 Recruiting
NCT06295926 2024-07-22
Serplulimab Combined With CCRT for LS-SCLC.
Peking Union Medical College Hospital
Phase 2 Recruiting
NCT04562337 2024-07-03
SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC
Shandong Cancer Hospital and Institute
Phase 2 Active not recruiting
NCT05765825 2024-06-20
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
Sichuan University
Phase 2 Recruiting
NCT06217757 2024-05-13
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sichuan University
Phase 1/2 Recruiting
NCT06375109 2024-04-19
NeoSCLC-001
Beijing Chest Hospital, Capital Medical University
Phase 2 Not yet recruiting
NCT03699956 2024-03-26
REPLATINUM
EpicentRx, Inc.
Phase 3 Terminated
NCT06306560 2024-03-12
A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.
Harbin Medical University
Phase 2 Not yet recruiting
NCT05092412 2024-01-12
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
Sichuan University
Phase 2 Unknown
NCT06177925 2023-12-20
A Phase â…¡ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
Nanfang Hospital, Southern Medical University
Phase 2 Recruiting
NCT02580994 2023-12-11
REACTION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02797977 2023-06-22
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Sierra Oncology LLC - a GSK company
Phase 1/2 Completed
NCT01642251 2023-05-06
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00453154 2023-04-04
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00526396 2023-03-24
STAD-1
National Cancer Institute, Naples
Phase 3 Unknown
NCT03066778 2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05484583 2022-08-05
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT05245994 2022-02-18
An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese
Sun Yat-sen University
Phase 2 Unknown
NCT02934503 2021-11-16
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
NYU Langone Health
Phase 2 Terminated
NCT00826644 2021-08-09
COMBAT
Chonnam National University Hospital
Phase 3 Completed
NCT04490421 2021-02-08
Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
Fuzhou General Hospital
Phase 3 Unknown
NCT02337712 2021-01-27
Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT00887159 2021-01-05
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
National Cancer Institute (NCI)
Phase 2 Completed
NCT03116971 2020-09-16
Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)
EMD Serono
Phase 1 Terminated
NCT01859741 2020-09-09
PINNACLE
Mereo BioPharma
Phase 1/2 Terminated
NCT01450761 2020-07-08
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Bristol-Myers Squibb
Phase 3 Completed
NCT04363255 2020-04-28
First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC
Taizhou Hospital
Phase 2 Unknown
NCT02819999 2020-03-12
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
AbbVie
Phase 1 Terminated
NCT03585998 2020-03-02
Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer
Samsung Medical Center
Phase 2 Unknown
NCT00613626 2020-02-11
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed